blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3110816

EP3110816 - N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.07.2020
Database last updated on 13.09.2024
FormerThe patent has been granted
Status updated on  17.05.2019
FormerGrant of patent is intended
Status updated on  01.01.2019
FormerExamination is in progress
Status updated on  28.12.2017
FormerRequest for examination was made
Status updated on  02.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Cancer Research Technology Ltd
Angel Building 407 St John Street
London, EC1V 4AD / GB
[2017/01]
Inventor(s)01 / WOODWARD, Hannah
c/o Cancer Research UK
Cancer Therapeutics Unit
Division of Cancer Therapeutics The Institute of Cancer Research
London SM2 5NG / GB
02 / INNOCENTI, Paolo
c/o Cancer Research UK
Cancer Therapeutics Unit
Division of Cancer Therapeutics The Institute of Cancer Research
London SM2 5NG / GB
03 / NAUD, Sebastien
c/o Cancer Research UK
Cancer Therapeutics Unit
Division of Cancer Therapeutics The Institute of Cancer Research
London SM2 5NG / GB
04 / BLAGG, Julian
c/o Cancer Research UK
Cancer Therapeutics Unit
Division of Cancer Therapeutics The Institute of Cancer Research
London SM2 5NG / GB
05 / HOELDER, Swen
c/o Cancer Research UK
Cancer Therapeutics Unit
Division of Cancer Therapeutics The Institute of Cancer Research
London SM2 5NG / GB
 [2017/01]
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[N/P]
Former [2017/01]HGF Limited
4th Floor
Merchant Exchange
17-19 Whitworth Street West
Manchester M1 5WG / GB
Application number, filing date15707759.527.02.2015
[2017/01]
WO2015GB50590
Priority number, dateGB2014000353628.02.2014         Original published format: GB 201403536
[2017/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015128676
Date:03.09.2015
Language:EN
[2015/35]
Type: A1 Application with search report 
No.:EP3110816
Date:04.01.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 03.09.2015 takes the place of the publication of the European patent application.
[2017/01]
Type: B1 Patent specification 
No.:EP3110816
Date:19.06.2019
Language:EN
[2019/25]
Search report(s)International search report - published on:EP03.09.2015
ClassificationIPC:C07D471/04, C07D519/00, A61K31/519, A61P35/00
[2017/01]
CPC:
C07D471/04 (EP,RU,US); A61K31/519 (EP,RU,US); A61P35/00 (EP,RU);
A61P43/00 (EP); C07D519/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/01]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:N2-PHENYL-PYRIDO[3,4-D]PYRIMIDIN-2,8-DIAMIN- DERIVATE UND IHRE VERWENDUNG ALS MPS1 INHIBITOREN[2019/02]
English:N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS[2017/01]
French:DÉRIVÉS DE N2-PHÉNYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE MPS1[2019/02]
Former [2017/01]N2-PHENYL-PYRIDO[3,4-D]PYRIMIDIN-2,8-DIAMIN-DERIVATE UND DEREN VERWENDUNG ALS MPS1-INHIBITOREN
Former [2017/01]DÉRIVÉS DE N2-PHÉNYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE ET LEUR UTILISATION COMME INHIBITEURS DE MPS1
Entry into regional phase30.08.2016National basic fee paid 
30.08.2016Designation fee(s) paid 
30.08.2016Examination fee paid 
Examination procedure30.08.2016Examination requested  [2017/01]
30.08.2016Date on which the examining division has become responsible
21.12.2017Despatch of a communication from the examining division (Time limit: M04)
24.04.2018Reply to a communication from the examining division
18.06.2018Despatch of a communication from the examining division (Time limit: M04)
19.10.2018Reply to a communication from the examining division
02.01.2019Communication of intention to grant the patent
07.05.2019Fee for grant paid
07.05.2019Fee for publishing/printing paid
07.05.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19173169.4  / EP3575299
Opposition(s)03.06.2020No opposition filed within time limit [2020/33]
Fees paidRenewal fee
01.02.2017Renewal fee patent year 03
01.02.2018Renewal fee patent year 04
05.02.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.02.2015
AL19.06.2019
AT19.06.2019
CY19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
MK19.06.2019
MT19.06.2019
PL19.06.2019
RO19.06.2019
RS19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
IE27.02.2020
LU27.02.2020
[2022/32]
Former [2022/28]HU27.02.2015
AL19.06.2019
AT19.06.2019
CY19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
MT19.06.2019
PL19.06.2019
RO19.06.2019
RS19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
IE27.02.2020
LU27.02.2020
Former [2021/08]AL19.06.2019
AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
PL19.06.2019
RO19.06.2019
RS19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
IE27.02.2020
LU27.02.2020
Former [2020/50]AL19.06.2019
AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
PL19.06.2019
RO19.06.2019
RS19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
LU27.02.2020
Former [2020/48]AL19.06.2019
AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
PL19.06.2019
RO19.06.2019
RS19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
LU27.02.2020
Former [2020/37]AL19.06.2019
AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
PL19.06.2019
RO19.06.2019
RS19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/36]AL19.06.2019
AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
PL19.06.2019
RO19.06.2019
RS19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/24]AL19.06.2019
AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
PL19.06.2019
RO19.06.2019
RS19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
PT21.10.2019
IS24.02.2020
Former [2020/22]AL19.06.2019
AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RO19.06.2019
RS19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/17]AL19.06.2019
AT19.06.2019
CZ19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RO19.06.2019
RS19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/14]AL19.06.2019
AT19.06.2019
CZ19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RO19.06.2019
RS19.06.2019
SK19.06.2019
SM19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/12]AL19.06.2019
AT19.06.2019
CZ19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RO19.06.2019
RS19.06.2019
SK19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/11]AL19.06.2019
AT19.06.2019
CZ19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RO19.06.2019
RS19.06.2019
SK19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
PT21.10.2019
Former [2020/10]AL19.06.2019
AT19.06.2019
CZ19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RO19.06.2019
RS19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
PT21.10.2019
Former [2020/09]AL19.06.2019
CZ19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RS19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
Former [2019/51]AL19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RS19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
Former [2019/50]AL19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RS19.06.2019
NO19.09.2019
GR20.09.2019
Former [2019/47]FI19.06.2019
LT19.06.2019
NO19.09.2019
Cited inInternational search[A]WO2012101032  (NERVIANO MEDICAL SCIENCES SRL [IT], et al);
 [A]WO2012123745  (CANCER REC TECH LTD [GB], et al);
 [XP]WO2014037750  (CANCER REC TECH LTD [GB])
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.